156 related articles for article (PubMed ID: 38436260)
1. Biomarker cystatin B expression correlates with pathogenesis in cervical cancer.
Ye D; Duan X; Guan B; Yuan J; Zhu Y; Shi J; Lu Q; Xu G
J Int Med Res; 2024 Mar; 52(3):3000605241233959. PubMed ID: 38436260
[TBL] [Abstract][Full Text] [Related]
2. Expression and epigenetic regulation of cystatin B in lung cancer and colorectal cancer.
Ma Y; Chen Y; Petersen I
Pathol Res Pract; 2017 Dec; 213(12):1568-1574. PubMed ID: 29037838
[TBL] [Abstract][Full Text] [Related]
3. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
4. Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway.
Wang X; Gui L; Zhang Y; Zhang J; Shi J; Xu G
Int J Oncol; 2014 Apr; 44(4):1099-106. PubMed ID: 24452274
[TBL] [Abstract][Full Text] [Related]
5. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy and glycolysis in PDAC.
Jiang Y; Han L; Xue M; Wang T; Zhu Y; Xiong C; Shi M; Li H; Hai W; Huo Y; Shen B; Jiang L; Chen H
Clin Transl Med; 2022 Dec; 12(12):e1126. PubMed ID: 36495123
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor‑β/miR‑143‑3p/cystatin B axis is a therapeutic target in human ovarian cancer.
Guan W; Wang X; Lin Q; Zhang J; Ren W; Xu G
Int J Oncol; 2019 Jul; 55(1):267-276. PubMed ID: 31180557
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of lncRNA-mRNA co-expression networks in HPV-driven cervical cancer reveals the pivotal function of LINC00511-PGK1 in tumorigenesis.
Xin X; Jia-Yin Y; Jun-Yang H; Rui W; Xiong-Ri K; Long-Rui D; Liu J; Jue-Yu Z
Comput Biol Med; 2023 Jun; 159():106943. PubMed ID: 37099974
[TBL] [Abstract][Full Text] [Related]
8. Gene-Expression Profiling Suggests Impaired Signaling via the Interferon Pathway in Cstb-/- Microglia.
Körber I; Katayama S; Einarsdottir E; Krjutškov K; Hakala P; Kere J; Lehesjoki AE; Joensuu T
PLoS One; 2016; 11(6):e0158195. PubMed ID: 27355630
[TBL] [Abstract][Full Text] [Related]
9. Abnormal microglial activation in the Cstb(-/-) mouse, a model for progressive myoclonus epilepsy, EPM1.
Okuneva O; Körber I; Li Z; Tian L; Joensuu T; Kopra O; Lehesjoki AE
Glia; 2015 Mar; 63(3):400-11. PubMed ID: 25327891
[TBL] [Abstract][Full Text] [Related]
10. CSTB Downregulation Promotes Cell Proliferation and Migration and Suppresses Apoptosis in Gastric Cancer SGC-7901 Cell Line.
Zhang J; Shi Z; Huang J; Zou X
Oncol Res; 2016 Oct; 24(6):487-494. PubMed ID: 28281969
[TBL] [Abstract][Full Text] [Related]
11. Gene expression alterations in the cerebellum and granule neurons of Cstb(-/-) mouse are associated with early synaptic changes and inflammation.
Joensuu T; Tegelberg S; Reinmaa E; Segerstråle M; Hakala P; Pehkonen H; Korpi ER; Tyynelä J; Taira T; Hovatta I; Kopra O; Lehesjoki AE
PLoS One; 2014; 9(2):e89321. PubMed ID: 24586687
[TBL] [Abstract][Full Text] [Related]
12. Seizures induce widespread upregulation of cystatin B, the gene mutated in progressive myoclonus epilepsy, in rat forebrain neurons.
D'Amato E; Kokaia Z; Nanobashvili A; Reeben M; Lehesjoki AE; Saarma M; Lindvall O
Eur J Neurosci; 2000 May; 12(5):1687-95. PubMed ID: 10792446
[TBL] [Abstract][Full Text] [Related]
13. Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations.
Canafoglia L; Gennaro E; Capovilla G; Gobbi G; Boni A; Beccaria F; Viri M; Michelucci R; Agazzi P; Assereto S; Coviello DA; Di Stefano M; Rossi Sebastiano D; Franceschetti S; Zara F
Epilepsia; 2012 Dec; 53(12):2120-7. PubMed ID: 23205931
[TBL] [Abstract][Full Text] [Related]
14. Cystatin B: mutation detection, alternative splicing and expression in progressive myclonus epilepsy of Unverricht-Lundborg type (EPM1) patients.
Joensuu T; Kuronen M; Alakurtti K; Tegelberg S; Hakala P; Aalto A; Huopaniemi L; Aula N; Michellucci R; Eriksson K; Lehesjoki AE
Eur J Hum Genet; 2007 Feb; 15(2):185-93. PubMed ID: 17003839
[TBL] [Abstract][Full Text] [Related]
15. The Role of NMP22 and CSTB Levels in Predicting Postoperative Recurrence of Bladder Cancer.
Huang C; Ai X; Hu L; Ren D
J Immunol Res; 2022; 2022():6735310. PubMed ID: 35647202
[TBL] [Abstract][Full Text] [Related]
16. Cystatin B and SOD1: protein–protein interaction and possible relation to neurodegeneration.
Ulbrich L; Cozzolino M; Marini ES; Amori I; De Jaco A; Carrì MT; Augusti-Tocco G
Cell Mol Neurobiol; 2014 Mar; 34(2):205-13. PubMed ID: 24234043
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance and Prognostic Value of Lactate Dehydrogenase Expression in Cervical Cancer.
Ye Y; Chen M; Chen X; Xiao J; Liao L; Lin F
Genet Test Mol Biomarkers; 2022 Mar; 26(3):107-117. PubMed ID: 35349377
[No Abstract] [Full Text] [Related]
18. Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
Koopaie M; Ghafourian M; Manifar S; Younespour S; Davoudi M; Kolahdooz S; Shirkhoda M
BMC Cancer; 2022 Apr; 22(1):473. PubMed ID: 35488257
[TBL] [Abstract][Full Text] [Related]
19. Loss of lysosomal association of cystatin B proteins representing progressive myoclonus epilepsy, EPM1, mutations.
Alakurtti K; Weber E; Rinne R; Theil G; de Haan GJ; Lindhout D; Salmikangas P; Saukko P; Lahtinen U; Lehesjoki AE
Eur J Hum Genet; 2005 Feb; 13(2):208-15. PubMed ID: 15483648
[TBL] [Abstract][Full Text] [Related]
20. Cystatin-B Negatively Regulates the Malignant Characteristics of Oral Squamous Cell Carcinoma Possibly
Xu TT; Zeng XW; Wang XH; Yang LX; Luo G; Yu T
Front Oncol; 2021; 11():707066. PubMed ID: 34504787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
